Menu
GeneBe

rs28897731

Variant summary

Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6

The NM_000059.4(BRCA2):c.4928T>C(p.Val1643Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000398 in 1,607,312 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V1643E) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000043 ( 0 hom. )

Consequence

BRCA2
NM_000059.4 missense

Scores

3
13

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:4B:12

Conservation

PhyloP100: -0.0600
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -3 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.089133054).
BP6
Variant 13-32339283-T-C is Benign according to our data. Variant chr13-32339283-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 51743.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=8, Benign=2, Uncertain_significance=2}.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
BRCA2NM_000059.4 linkuse as main transcriptc.4928T>C p.Val1643Ala missense_variant 11/27 ENST00000380152.8

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
BRCA2ENST00000380152.8 linkuse as main transcriptc.4928T>C p.Val1643Ala missense_variant 11/275 NM_000059.4 A2

Frequencies

GnomAD3 genomes
AF:
0.00000657
AC:
1
AN:
152142
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000287
AC:
7
AN:
244196
Hom.:
0
AF XY:
0.0000378
AC XY:
5
AN XY:
132218
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000104
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000269
Gnomad OTH exome
AF:
0.000170
GnomAD4 exome
AF:
0.0000433
AC:
63
AN:
1455170
Hom.:
0
Cov.:
44
AF XY:
0.0000415
AC XY:
30
AN XY:
723614
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000231
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000947
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000441
Gnomad4 OTH exome
AF:
0.0000500
GnomAD4 genome
AF:
0.00000657
AC:
1
AN:
152142
Hom.:
0
Cov.:
33
AF XY:
0.0000135
AC XY:
1
AN XY:
74318
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000207
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000465
Hom.:
0
Bravo
AF:
0.00000756
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.00
AC:
0
ExAC
AF:
0.0000494
AC:
6
EpiCase
AF:
0.00
EpiControl
AF:
0.0000593

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:4Benign:12
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:1Benign:4
Benign, no assertion criteria providedclinical testingSharing Clinical Reports Project (SCRP)May 01, 2012- -
Benign, criteria provided, single submitterclinical testingAll of Us Research Program, National Institutes of HealthDec 18, 2023- -
Likely benign, criteria provided, single submitterclinical testingMendelicsMay 28, 2019- -
Uncertain significance, no assertion criteria providedclinical testingBreast Cancer Information Core (BIC) (BRCA2)Feb 20, 2004- -
Likely benign, criteria provided, single submitterclinical testingMichigan Medical Genetics Laboratories, University of MichiganApr 21, 2016- -
not provided Uncertain:2Benign:2
Likely benign, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenApr 01, 2022BRCA2: BP1, BP4 -
Uncertain significance, criteria provided, single submitterclinical testingInstitute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU DresdenNov 03, 2021- -
Likely benign, criteria provided, single submitterclinical testingGeneDxJun 04, 2019This variant is associated with the following publications: (PMID: 27062684, 18951461, 24916970, 21203900, 26207792, 18824701, 18279628, 27741520, 21702907, 25348012, 27527004, 30606148, 32806537) -
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoNov 20, 2020- -
Hereditary cancer-predisposing syndrome Benign:3
Likely benign, criteria provided, single submittercurationUniversity of Washington Department of Laboratory Medicine, University of WashingtonMar 23, 2023Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). -
Benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthMay 24, 2016- -
Likely benign, criteria provided, single submitterclinical testingAmbry GeneticsJan 24, 2019This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Hereditary breast ovarian cancer syndrome Uncertain:1Benign:1
Likely benign, criteria provided, single submitterclinical testingInvitaeJan 24, 2024- -
Uncertain significance, no assertion criteria providedclinical testingCancer Genetics and Genomics Laboratory, British Columbia Cancer AgencyApr 14, 2016- -
not specified Benign:1
Likely benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpDec 18, 2023Variant summary: BRCA2 c.4928T>C (p.Val1643Ala) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.9e-05 in 1600364 control chromosomes (gnomAD). This frequency is not higher than the estimated maximum expected for a pathogenic variant in BRCA2 causing Hereditary Breast And Ovarian Cancer Syndrome (0.00075), allowing no conclusion about variant significance. c.4928T>C has been reported in the literature in individuals affected with breast or ovarian cancer without strong evidence of causality (e.g. Konecny_2011, Lu_2012, Peixoto_2014, Spearman_2008, Fanale_2021, Dorling_2021), and was also found in controls (Dorling_2021). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. Co-occurrences with other pathogenic variants have been reported (BRCA1 c.5263_5264insC, p.Ser1755?fs and BRCA2 c.9976A>T, p.Lys3326Ter in the BIC database), providing supporting evidence for a benign role. At least one publication reports experimental evidence evaluating an impact on protein function (Biswas_2020). These results showed no damaging effect of this variant in a well-established mouse embryonic stem cell based assay examining the ability to rescue the lethality of BRCA2-null mESC as well as sensitivity to six DNA damaging agents including ionizing radiation and a PARP inhibitor. The following publications have been ascertained in the context of this evaluation (PMID: 33293522, 21702907, 21203900, 22476429, 24916970, 18824701, 33471991, 31131967, 34178674). 12 other submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and reported the variant with conflicting assessments and a majority consensus as likely benign/benign (n=9) (VUS, n=3). Based on the evidence outlined above, the variant was classified as likely benign. -
Malignant tumor of breast Benign:1
Likely benign, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-The BRCA2 p.Val1643Ala variant was identified in 1 of 698 proband chromosomes (frequency: 0.001) from individuals or families with breast or ovarian cancer and was found not to segregate with disease in the proband’s two family members with breast cancer (Fernandes 2016). The variant was also identified in dbSNP (ID: rs28897731) as "With other allele", ClinVar (classified as benign by SCRP; as likely benign by GeneDx, Ambry Genetics, Invitae, and Michigan Medical Genetics; and as uncertain significance by Humangenetik Teubingen, COGR, and BIC), and LOVD 3.0 (classified as uncertain or NA by 3 submitters). The variant has been identified by our laboratory in at least three individuals with breast cancer; one of whom also has a co-occurring pathogenic ATM variant (c.5712dup, p.Ser1905Ilefs*25). The variant was identified in control databases in 7 of 239572 chromosomes at a frequency of 0.00003 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Latino in 1 of 32346 chromosomes (freq: 0.00003), European in 3 of 109484 chromosomes (freq: 0.00003), and South Asian in 3 of 28946 chromosomes (freq: 0.0001); it was not observed in the African, Other, Ashkenazi Jewish, East Asian, or Finnish populations. The p.Val1643 residue is not conserved in mammals and 5 of 5 computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.10
BayesDel_addAF
Benign
-0.30
T
BayesDel_noAF
Benign
-0.46
Cadd
Benign
7.0
Dann
Uncertain
0.98
Eigen
Benign
-1.0
Eigen_PC
Benign
-1.0
FATHMM_MKL
Benign
0.072
N
M_CAP
Benign
0.067
D
MetaRNN
Benign
0.089
T;T
MetaSVM
Benign
-0.90
T
MutationTaster
Benign
1.0
N;N
PrimateAI
Benign
0.19
T
PROVEAN
Uncertain
-2.7
D;D
REVEL
Benign
0.18
Sift
Uncertain
0.026
D;D
Sift4G
Benign
0.18
T;T
Vest4
0.18
MVP
0.70
MPC
0.022
ClinPred
0.052
T
GERP RS
-5.9
gMVP
0.13

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs28897731; hg19: chr13-32913420; API